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PD-L1, PD-L2 and other immune-related molecules reg-
ulate Th1 and Th2 immune responses. Tumor-expressed
PD-L1, when bound to PD-1 or B7.1 on activated T cells,
can mediate cancer immune evasion. While inhibiting
PD-L1 receptor binding represents an attractive strategy
to restore tumor-specific T-cell immunity, other
immune-related factors and cell types within the tumor
microenvironment affect anti-tumor T-cell responses.
MPDL3280A, a human mAb containing an engineered
Fc-domain designed to optimize efficacy and safety and
to promote Th1-driven responses, is described here with
PhI biomarker results. MPDL3280A was administered IV
q3w in >300 pts with locally advanced or metastatic solid
tumors. ORR was assessed by RECIST v1.1, including
u/cCR and u/cPR. PD-L1 and CD8 were measured by
IHC. The expression of ≈90 immune-related markers,
including PD-L1 and PD-L2, were evaluated at baseline
(BL) and on-treatment. BL tumor samples were available
for 103 pts, and matched on-treatment samples were avail-
able for 26 pts. As of Feb 1, 2013, 140 pts enrolled prior to
Aug 1, 2012 were evaluable for efficacy. Responses were
observed in multiple tumor types including NSCLC
(9/41), RCC (6/47), melanoma (11/38), CRC (1/4) and gas-
tric cancer (1/1). An ORR of 21% (29/140) was observed in
nonselected solid tumors with a duration of response of
1+ to 253+ days. Elevated pretreatment PD-L1 expression
(IHC) was associated with response to MPDL3280A, and
coordinated expression of PD-L1 and CD8+ T cells was
seen. The ORR was 36% (13/36) for pts with PD-L1-pos
tumors vs 13% (9/67) for pts with PD-L1-neg tumors.
81 pts had tumors evaluable for PD-L2. Median PD-L2
expression was ≈2x higher in PD-L1-pos tumors vs PD-
L1-neg tumors. A T-cell gene signature (eg, CD8, EOMES,
IFNg, Granzyme A) was associated with treatment
response. On treatment, responding tumors had increased
PD-L1 expression and a Th1-dominant immune infiltrate,
evidence of adaptive PD-L1 upregulation. Nonresponders
showed minimal tumor CD8+ T-cell infiltration and an
absence of T-cell activation. Additionally, elevated expres-
sion of immune suppressors, including FOXP3 and
RORC, correlated with lack of response. Both the presence
of Th1-related CD8 biology at BL and adaptive tumor PD-
L1 enhancement with MPDL3280A treatment correlated
with tumor response, as did PD-L1 status. Updated data
will be presented.
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